04:39 AM EST, 01/10/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said late Thursday it has struck a licensing agreement to use MediLink Therapeutics' Tmalin antibody-drug conjugate platform for the development of its ZL-6201 investigational drug.

Financial terms were not disclosed.

Zai Lab ( ZLAB ) said the partnership will expand its oncology pipeline with another drug targeting multiple solid tumors.